Through this application M. D. Anderson Cancer Center seeks funding for a new Prostate Cancer SPORE. Under the leadership of Dr. Christopher J. Logothetis, Principal Investigator, and Dr. Timothy C. Thompson, Co-Principal Investigator, who are recognized internationally for their research in prostate cancer, the M. D. Anderson Cancer Center Prostate SPORE has created a stable and dynamic infrastructure for translational research that works toward the development of non-morbid therapies for patients with localized prostate cancer;the identification of predictive biomarkers for therapeutic response;the development of new biologically targeted therapeutic agents;and the linkage of epidemiological and molecular signaling profiles for virulent prostate cancer. We continue to build on our capacity to conduct novel and innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal we define our translational research objectives as (1) development of quantitative tools for determination of aggressive prostate cancers;(2) testing of novel therapeutic agents in proof of principle clinical trials;(3) development of predictive biomarkers for identification of patients who will respond to targeted therapies;and (4) development of rational strategies for combination therapies. We will achieve these translational research objectives by identifying and testing obesity-related biomarkers for virulent prostate cancer, clinical testing of GLIPR1-ATM protein and a novel ligand-directed pro-apoptotic peptide (BMTP-11) for prostate cancer, and conducting two hypothesis-driven clinical trials with a novel FGF signaling inhibitor (TKl 258), and combination Src inhibitor (Dasatinib)+Docetaxel in patients with advanced prostate cancer. We will accomplish our goals through 5 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Specimen), a dynamic Developmental Research Program and an effective Career Development Program. We are optimistic that our research efforts will contribute to reductions in the incidence of, and morbidity and mortality from, this devastating disease by translating basic research into clinical practice.

Public Health Relevance

New and effective therapies for prostate cancer are desperately needed. To address this need, the M.D. Anderson Cancer Center Prostate SPORE will build on its capacity to conduct novel and innovative clinical trials through the execution of translational research projects that will test novel therapeutic agents in proof-of-principle clinical trials and develop quantitative tools and predictive biomarkers for single and combination targeted therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140388-05
Application #
8541596
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2009-09-02
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$2,150,500
Indirect Cost
$724,172
Name
University of Texas MD Anderson Cancer Center
Department
Dentistry
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Tao; Tseng, Chieh; Zhang, Yan et al. (2016) CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 7:11674
Sun, Sheng; Sun, Le; Zhou, Xi et al. (2016) Phosphorylation-Dependent Activation of the ESCRT Function of ALIX in Cytokinetic Abscission and Retroviral Budding. Dev Cell 36:331-43
Hosoya, Hitomi; Dobroff, Andrey S; Driessen, Wouter H P et al. (2016) Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A 113:1877-82
Maity, Sankar N; Titus, Mark A; Gyftaki, Revekka et al. (2016) Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep 6:35354
Saha, Achinto; Blando, Jorge; Fernandez, Irina et al. (2016) Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7:25194-207
Han, Ying; Rand, Kristin A; Hazelett, Dennis J et al. (2016) Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. J Natl Cancer Inst 108:
Varkaris, Andreas; Corn, Paul G; Parikh, Nila U et al. (2016) Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22:107-21
Fong, Eliza L S; Wan, Xinhai; Yang, Jun et al. (2016) A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77:164-72
Weiderhold, Kimberly N; Fadri-Moskwik, Maria; Pan, Jing et al. (2016) Dynamic Phosphorylation of NudC by Aurora B in Cytokinesis. PLoS One 11:e0153455
Qiao, Yuanyuan; Feng, Felix Y; Wang, Yugang et al. (2016) Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia 18:1-9

Showing the most recent 10 out of 167 publications